Verici Dx (VRCI) H1 2024 earnings summary

Executive summary

• Transitioned from research and product development to commercial stage, establishing three main revenue streams: licensing, direct sales, and services.

• Commercialized two kidney transplant tests: Clarava (pre-transplant, licensed to Thermo Fisher) and Tutivia (early post-transplant, direct sales), with ProTega (late stage) in development.

• Achieved significant operational milestones, including expanded US market access, new collaborations, and leveraging a research asset of physical samples and transcriptome data.

• Strengthened financial position via $8.2m equity fundraise and Thermo Fisher agreement, extending cash runway into 2026.

Financial highlights

• Revenue of $3.3 million in H1 2024, primarily from licensing and services.

• EBITDA loss of $1.1 million, reflecting tight cost control.

• Net loss of $1.3 million for H1 2024.

• Cash balance at 30 June 2024 was $7 million, boosted by a $7.5 million fundraise.

• Cash outflow from operations was $3.2 million for the six months.

Outlook and guidance

• Medicare reimbursement determination for Tutivia expected by end of 2024, with potential for retrospective reimbursement.

• ProTega validation and market entry expected in H1 2025, with clinical trial extended to 24 months.

• Cash runway extends into 2026 based on current assumptions and funding.

• Anticipates further expansion of sales team in response to increased demand.